---
title: "Otezla (apremilast) in plaque psoriasis: Specific populations questions"
description: "Specific populations questions on Otezla (apremilast) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: Can Otezla XR be used in children with plaque psoriasis? At what age and weight can children take Otezla for plaque psoriasis? Does Otezla affect growth in children? Is Otezla safe for adults 65 and older with plaque psoriasis? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast) in plaque psoriasis: Specific populations questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)

Specific populations questions that apply to every indication of Otezla are on [Otezla (apremilast), all indications: Specific populations](https://www.evicenter.com/medical-information/otezla/specific-populations).

## Pediatric use

<a id="otezla-xr-children"></a>

### Can Otezla XR be used in children with plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)

> “The safety and effectiveness of OTEZLA XR have been established for the treatment of moderate to 
> severe plaque psoriasis and psoriatic arthritis in pediatric patients 6 years of age and older and weighing 
> at least 50 kg. Use of OTEZLA XR in these patients is supported by pharmacokinetic data from healthy 
> adults demonstrating comparable PK exposure between OTEZLA XR 75 mg once daily and OTEZLA 
> 30 mg twice daily, which is the recommended OTEZLA dosage for pediatric patients weighing at least 
> 50 kg [see Dosage and Administration (2.1), Clinical Pharmacology (12.3)].”

Source: [OTEZLA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=15)

> “The safety and effectiveness of OTEZLA XR have not been established in pediatric patients below the 
> age of 6 years or weighing less than 50 kg with moderate to severe plaque psoriasis or psoriatic arthritis.”

Source: [OTEZLA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=15)

<a id="otezla-children-age-weight"></a>

### At what age and weight can children take Otezla for plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)

> “In the pediatric population, OTEZLA is indicated for patients weighing at 
> least 20 kg, and OTEZLA XR is indicated for patients weighing at least 50 kg.”

Source: [OTEZLA: Prescribing information, page 1, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=1)

> “The safety and effectiveness of OTEZLA have been established in pediatric patients 6 years of age and 
> older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for 
> phototherapy or systemic therapy. Use of OTEZLA in these patients is supported by evidence from a 
> 52-week adequate and well-controlled clinical trial (PSOR-6) in 245 pediatric subjects 6 years of age and 
> older with moderate to severe plaque psoriasis. Weight loss in OTEZLA-treated pediatric subjects was 
> comparable to weight loss observed in adults [see Warnings and Precautions (5.4), Adverse Reactions 
> (6.1) and Clinical Studies (14.3)].”

Source: [OTEZLA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=14)

> “The safety and effectiveness of OTEZLA have not been established in pediatric patients below the age of 
> 6 years or weighing less than 20 kg with moderate to severe plaque psoriasis.”

Source: [OTEZLA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=14)

<a id="otezla-children-growth"></a>

### Does Otezla affect growth in children?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)

> “Closely monitor growth (height and weight) in pediatric patients treated with OTEZLA/OTEZLA XR. 
> Pediatric patients who are not growing or gaining weight as expected may need to have their treatment 
> interrupted.”

Source: [OTEZLA: Prescribing information, page 8, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=8)

> “Weight loss in OTEZLA-treated pediatric subjects was 
> comparable to weight loss observed in adults”

Source: [OTEZLA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=14)

## Specific populations

<a id="otezla-older-adults"></a>

### Is Otezla safe for adults 65 and older with plaque psoriasis?

Applies to: Plaque psoriasis in adults who are candidates for phototherapy or systemic therapy

> “Of the 1257 subjects who enrolled in two placebo-controlled plaque psoriasis trials (PSOR-1 and 
> PSOR-2), a total of 108 (8.6%) plaque psoriasis patients were 65 years of age and older, including 9 
> (0.7%) patients who were 75 years of age and older. No overall differences were observed in the safety or 
> effectiveness in geriatric patients ≥ 65 years of age and younger adult patients < 65 years of age in the 
> clinical trials.”

Source: [OTEZLA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=15)

> “Because patients 65 years of age or older may be at a higher risk of complications such as volume 
> depletion or hypotension from severe diarrhea, nausea, or vomiting, monitor geriatric patients closely for 
> such complications [see Warnings and Precautions (5.2)].”

Source: [OTEZLA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=15)

## Related pages
- [Medical information: Otezla (apremilast): Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/dosing-and-administration)
